The ACOR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACOR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ACOR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ACOR Detailed Price Forecast - CNN Money||View ACOR Detailed Summary - Google Finance|
|View ACOR Detailed Summary - Yahoo! Finance||View ACOR Stock Research & Analysis - Zacks.com|
|View ACOR Trends & Analysis - Trade-Ideas||View ACOR Major Holders - Barrons|
|View ACOR Call Transcripts - NASDAQ||View ACOR Breaking News & Analysis - Seeking Alpha|
|View ACOR Annual Report - CompanySpotlight.com||View ACOR OTC Short Report - OTCShortReport.com|
|View ACOR Fundamentals - TradeKing||View ACOR SEC Filings - Bar Chart|
|View Historical Prices for ACOR - The WSJ||View Performance/Total Return for ACOR - Morningstar|
|View the Analyst Estimates for ACOR - MarketWatch||View the Earnings History for ACOR - CNBC|
|View the ACOR Earnings - StockMarketWatch||View ACOR Buy or Sell Recommendations - MacroAxis|
|View the ACOR Bullish Patterns - American Bulls||View ACOR Short Pain Metrics - ShortPainBot.com|
|View ACOR Stock Mentions - StockTwits||View ACOR Stock Mentions - PennyStockTweets|
|View ACOR Stock Mentions - Twitter||View ACOR Investment Forum News - Investor Hub|
|View ACOR Stock Mentions - Yahoo! Message Board||View ACOR Stock Mentions - Seeking Alpha|
|View Insider Transactions for ACOR - SECform4.com||View Insider Transactions for ACOR - Insider Cow|
|View ACOR Major Holdings Summary - CNBC||View Insider Disclosure for ACOR - OTC Markets|
|View Insider Transactions for ACOR - Yahoo! Finance||View Institutional Holdings for ACOR - NASDAQ|
|View ACOR Stock Insight & Charts - FinViz.com||View ACOR Investment Charts - StockCharts.com|
|View ACOR Stock Overview & Charts - BarChart||View ACOR User Generated Charts - Trading View|
Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled for May 2, 2019
Posted on Thursday April 18, 2019
Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.
Acorda to Gain From Inbrija Sales and Neurological Pipeline
Posted on Thursday April 11, 2019
Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.
See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
Posted on Tuesday April 09, 2019
Acorda Therapeutics Inc NASDAQ/NGS:ACORView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 28. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ACOR had net inflows of $2.35 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Acorda to Present New Long-Term Data for INBRIJA™ (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting
Posted on Tuesday March 19, 2019
Acorda Therapeutics, Inc. (ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa.